BR112021026334A2 - Macrófagos ativados por hdac6, composições, e usos dos mesmos - Google Patents

Macrófagos ativados por hdac6, composições, e usos dos mesmos

Info

Publication number
BR112021026334A2
BR112021026334A2 BR112021026334A BR112021026334A BR112021026334A2 BR 112021026334 A2 BR112021026334 A2 BR 112021026334A2 BR 112021026334 A BR112021026334 A BR 112021026334A BR 112021026334 A BR112021026334 A BR 112021026334A BR 112021026334 A2 BR112021026334 A2 BR 112021026334A2
Authority
BR
Brazil
Prior art keywords
hdac6
compositions
activated macrophages
macrophages
activated
Prior art date
Application number
BR112021026334A
Other languages
English (en)
Inventor
Alejandro Villagra
Nima Aghdam
Satish Noonepalle
Original Assignee
Medstar Health
The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medstar Health, The George Washington Univ A Congressionally Chartered Not For Profit Corporation filed Critical Medstar Health
Publication of BR112021026334A2 publication Critical patent/BR112021026334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

macrófagos ativados por hdac6,composições, e usos dos mesmos. a presente invenção refere-se a histone deacetilase 6 (hdac6)- macrófagos ativados, composições compreendendo macrófagos ativados pelo hdac6, métodos de produzir macrófagos ativados por hdac6, e métodos de tratamento de doenças, por exemplo, câncer, por administração de uma quantidade terapeuticamente efetiva de macrófagos ativados por hdac6.
BR112021026334A 2019-06-27 2020-06-26 Macrófagos ativados por hdac6, composições, e usos dos mesmos BR112021026334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867390P 2019-06-27 2019-06-27
PCT/US2020/040003 WO2020264437A1 (en) 2019-06-27 2020-06-26 Hdac6-activated macrophages, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
BR112021026334A2 true BR112021026334A2 (pt) 2022-05-10

Family

ID=74059971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026334A BR112021026334A2 (pt) 2019-06-27 2020-06-26 Macrófagos ativados por hdac6, composições, e usos dos mesmos

Country Status (8)

Country Link
US (1) US20220401474A1 (pt)
EP (1) EP3990618A4 (pt)
JP (1) JP2022538284A (pt)
CN (1) CN115443329A (pt)
AU (1) AU2020302928A1 (pt)
BR (1) BR112021026334A2 (pt)
CA (1) CA3144985A1 (pt)
WO (1) WO2020264437A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2022203429A1 (en) * 2021-03-26 2022-09-29 Chong Kun Dang Pharmaceutical Corp. Composition for preventing or treating multiple sclerosis
CN113387840B (zh) * 2021-06-10 2022-11-08 中国药科大学 PD-1/PD-L1和HDACs双靶点抑制剂、制备方法和用途
TW202328118A (zh) * 2021-10-29 2023-07-16 韓商鐘根堂股份有限公司 用於預防或治療特發性肺纖維化（ｉｐｆ）之組合物
TW202337446A (zh) * 2022-01-28 2023-10-01 韓商鐘根堂股份有限公司 用於預防或治療肺動脈高血壓之組合物
KR20230144686A (ko) * 2022-04-07 2023-10-17 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
WO2023217095A1 (en) * 2022-05-09 2023-11-16 Synrx Therapeutics (Hangzhou) Co., Ltd. Heterocyclic compound, pharmaceutical composition and use thereof
EP4338745A1 (en) * 2022-09-14 2024-03-20 Technische Universität Dresden Allogeneic human macrophages for cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123591A1 (en) * 2009-08-22 2011-05-26 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
JP6585041B2 (ja) * 2013-07-18 2019-10-02 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫細胞の能力を増強する方法
WO2015154065A1 (en) * 2014-04-05 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination
US11072777B2 (en) * 2016-03-04 2021-07-27 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
KR20200103764A (ko) * 2017-12-22 2020-09-02 아토사 테라퓨틱스, 인크. 유방 장애의 관내 치료 방법

Also Published As

Publication number Publication date
CA3144985A1 (en) 2020-12-30
CN115443329A (zh) 2022-12-06
JP2022538284A (ja) 2022-09-01
US20220401474A1 (en) 2022-12-22
EP3990618A4 (en) 2023-08-09
EP3990618A1 (en) 2022-05-04
WO2020264437A1 (en) 2020-12-30
AU2020302928A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
BR112021026334A2 (pt) Macrófagos ativados por hdac6, composições, e usos dos mesmos
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
AU2018284960A1 (en) AADC polynucleotides for the treatment of Parkinson's disease
PH12016501735B1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
JOP20190191A1 (ar) وحدات شجرية علاجية
PH12021550872A1 (en) Therapeutic compounds
TN2019000187A1 (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA202190153A1 (ru) Составы ингибитора axl/mer
WO2019217397A3 (en) Compositions and methods for improving strand biased
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112023004235A2 (pt) Macrófagos ativados por stat, composições e usos dos mesmos
MX364197B (es) Proceso de sintesis de hidroxi-triacilgliceroles y usos de los mismos para la prevencion y el tratamiento de enfermedades.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) ; MEDSTAR HEALTH, INC. (US)